Premium
Clinical‐scale generation of strongly CD83‐expressing dendritic cells using extracorporeal photopheresis
Author(s) -
Bredberg Anders,
Jonsson Svante,
Lindblom Anders,
Björk Peter
Publication year - 2007
Publication title -
photodermatology, photoimmunology and photomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.736
H-Index - 60
eISSN - 1600-0781
pISSN - 0905-4383
DOI - 10.1111/j.1600-0781.2007.00285.x
Subject(s) - leukapheresis , photopheresis , extracorporeal photopheresis , cd14 , medicine , dendritic cell , flow cytometry , immunology , immunotherapy , cutaneous t cell lymphoma , population , cancer research , antigen , immune system , lymphoma , biology , cd34 , stem cell , microbiology and biotechnology , mycosis fungoides , transplantation , environmental health , graft versus host disease
Background: Many strategies are currently being pursued in order to generate mature dendritic cells (DC) to be used for immunotherapy. A potent anti‐tumour influence by extracorporeal photopheresis has been documented for cutaneous T‐cell lymphoma, and a major mechanism of action has been suggested to be generation of DC presenting tumour antigens. Purpose: To determine the potential of a simple clinical photopheresis protocol for large‐scale development of mature DC. Methods: A standard monocyte‐enriched leukapheresis preparation of 10 9 –10 10 cells was derived during each of five consecutive treatment sessions of a patient with cutaneous T‐cell lymphoma. The cells were incubated overnight in autologous plasma with no addition of growth medium. Cell surface lymphocyte, monocyte and DC markers were determined using multi‐colour flow cytometry. Results: We find signs of activation of the CD14+ monocytes, as well as the appearance of a minor population of mature DC negative for CD14 but with strong CD83 expression. Conclusions: With a procedure appropriate for routine clinical use, a total number of 10 6 –10 7 DC ready for patient reinfusion can be prepared within 24 h. Our findings indicate the need to further explore the capacity of photopheresis to stimulate cancer patients' anti‐tumour defence reaction.